Epigenetic Activation of Plasmacytoid DCs Drives IFNAR-Dependent Therapeutic Differentiation of AML.
Jessica M SalmonIzabela TodorovskiKym L StanleyClaudia BruedigamConor J KearneyLuciano G MartelottoFernando J RosselloTimothy SempleGisela Mir ArnauMagnus ZethovenMichael BotsStefan BjelosevicLeonie A ClusePeter J FraserVeronique LitalienEva VidacsKate McArthurAntony Y MatthewsElise GressierNicole A de WeerdJens LichteMadison J KellySimon J HoggPaul J HertzogLev M KatsStephin J VervoortDaniel D De CarvalhoStefanie ScheuSammy BedouiBenjamin T KileSteven W LaneAndrew Charles PerkinsAndrew H WeiPilar M DominguezRicky W JohnstonePublished in: Cancer discovery (2022)
We demonstrate that HDACis induce terminal differentiation of AML through epigenetic remodeling of pDCs, resulting in production of type I IFN that is important for the therapeutic effects of HDACis. The study demonstrates the important functional interplay between the immune system and leukemias in response to HDAC inhibition. This article is highlighted in the In This Issue feature, p. 1397.